Evaluation of teriparatide treatment in adults with osteogenesis imperfecta

What Was Tested

The paper reports a study of Teriparatide, published as a randomized controlled trial.

Adults with osteogenesis imperfecta (OI) have a high risk of fracture.

Currently, few treatment options are available, and bone anabolic therapies have not been tested in clinical trials for OI treatment.

Who Took Part

According to the abstract, 79 adults were involved.

By PubMed's age tags, the people studied were teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

Secondary endpoints included percent change in bone remodeling markers and vertebral volumetric BMD (vBMD) by quantitative computed tomography, estimated vertebral strength by finite element analysis, and self-reported fractures.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The adults were allocated by chance, so the Teriparatide group and the comparison group should start out alike.

Neither the adults nor the staff measuring them knew who was on Teriparatide, so expectations could not easily colour the readings.

Some adults received a placebo instead of Teriparatide, giving a reference point.

The primary endpoint was the percent change in areal bone mineral density (aBMD) of the lumbar spine (LS), as determined by dual-energy X-ray absorptiometry.

What Was Measured

Currently, few treatment options are available, and bone anabolic therapies have not been tested in clinical trials for OI treatment.

The subject headings attached to it are Absorptiometry, Photon, Bone Density, Bone Density Conservation Agents, Bone Remodeling, Finite Element Analysis, Fractures, Bone and Lumbar Vertebrae.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Teriparatide in 79 adults.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (The Journal of clinical investigation), a journal based in United States.

More context: the Teriparatide compound page, all human trials.